SCHEMBL6932167

SCHEMBL6932167

Cn1c(NCCCn2ccnc2)nc(-c2ccncc2)c(-c2ccc(F)cc2)c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 4/20 0.54
POLB P06746 2/20 0.51
SCN9A Q15858 3/20 0.47
NAMPT P43490 3/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
HPGD P15428 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CYP19A1 P11511 1/20 0.44
ALOX15 P16050 1/20 0.43
MAPK14 Q16539 3/20 0.43
MAPK13 O15264 2/20 0.43
MAPK9 P45984 2/20 0.43
MAP4K4 O95819 1/20 0.43
EGFR P00533 1/20 0.43
ERBB2 P04626 1/20 0.43
LYN P07948 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6932796 0.86 MAPK14 (0.46) ALDH1A1MEN1TP53KMT2AHSD17B10
SCHEMBL6934249 0.85 MAPK14 (0.46) ALDH1A1MEN1TP53KMT2AHSD17B10
SCHEMBL6933043 0.83 MAPK14 (0.48) MAPK14MAPK13MAPK9MAP4K4EGFR
SCHEMBL6929508 0.83 CYP3A4 (0.55) MAPK14MAPK13MAPK9MAP4K4EGFR
SCHEMBL6934712 0.83 MAPK14 (0.47) HSD17B10MAPK14MAPK13MAPK9MAP4K4
SCHEMBL6931494 0.82 MAPK14 (0.54) MAPK14MAPK13MAPK9MAP4K4EGFR
SCHEMBL6932108 0.81 MAPK14 (0.52) MAPK14MAPK13MAPK9MAP4K4EGFR
SCHEMBL6934372 0.81 MAPK14 (0.46) HSD17B10MAPK14MAPK13MAPK9MAP4K4
SCHEMBL6936729 0.81 QPCT (0.53) QPCTPOLBSCN9ANAMPTKDM4E
SCHEMBL27505559 0.80 MAPK14 (0.47) QPCTMAPK14MAPK13MAPK9MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US claimed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US claimed
US-6649604-B2 Analgesics; antidiabetic agents; antiinflamamtory agents AMGEN INC. 2003-11-18 US disclosed
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 US disclosed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US disclosed
EP-0948496-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE Amgen inc. (US) 1999-10-13 EP disclosed
WO-1998024780-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073704-A1 Substituted pyridone compounds and methods of use IL6, IL1B, IL1A QPCT 1372/4885POLB 1406/4885SCN9A 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.